JP2018509393A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509393A5
JP2018509393A5 JP2017541310A JP2017541310A JP2018509393A5 JP 2018509393 A5 JP2018509393 A5 JP 2018509393A5 JP 2017541310 A JP2017541310 A JP 2017541310A JP 2017541310 A JP2017541310 A JP 2017541310A JP 2018509393 A5 JP2018509393 A5 JP 2018509393A5
Authority
JP
Japan
Prior art keywords
seq
dosage form
unit dosage
polypeptide
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017541310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509393A (ja
JP6794363B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/016842 external-priority patent/WO2016127097A1/en
Publication of JP2018509393A publication Critical patent/JP2018509393A/ja
Publication of JP2018509393A5 publication Critical patent/JP2018509393A5/ja
Application granted granted Critical
Publication of JP6794363B2 publication Critical patent/JP6794363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017541310A 2015-02-06 2016-02-05 認知の向上のための方法および組成物 Active JP6794363B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113300P 2015-02-06 2015-02-06
US62/113,300 2015-02-06
PCT/US2016/016842 WO2016127097A1 (en) 2015-02-06 2016-02-05 Methods and compositions for improved cognition

Publications (3)

Publication Number Publication Date
JP2018509393A JP2018509393A (ja) 2018-04-05
JP2018509393A5 true JP2018509393A5 (https=) 2019-03-22
JP6794363B2 JP6794363B2 (ja) 2020-12-02

Family

ID=56564770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541310A Active JP6794363B2 (ja) 2015-02-06 2016-02-05 認知の向上のための方法および組成物

Country Status (8)

Country Link
US (6) US10632180B2 (https=)
EP (2) EP3253403B1 (https=)
JP (1) JP6794363B2 (https=)
CN (2) CN121102455A (https=)
AU (2) AU2016215080B2 (https=)
CA (1) CA2974988A1 (https=)
HK (1) HK1246193A1 (https=)
WO (1) WO2016127097A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016215080B2 (en) 2015-02-06 2020-12-24 The Regents Of The University Of California Methods and compositions for improved cognition
EP3377091B1 (en) 2015-11-19 2023-09-20 Universitat Autònoma de Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments
JP2018184369A (ja) * 2017-04-26 2018-11-22 株式会社明治 知的作業能力向上用組成物および認知能力向上用組成物
US12227777B2 (en) * 2018-01-12 2025-02-18 New York University Soluble alpha-Klotho proteins, protein fragments, and uses thereof
WO2019222629A1 (en) * 2018-05-17 2019-11-21 Neuralstem, Inc. Amelioration of cognitive and motor deficits associated with alzheimer's
CA3120701A1 (en) * 2018-11-21 2020-05-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for reducing age-related striated muscle and cognitive decline
EP4103223A4 (en) 2020-02-12 2024-05-29 The Regents of the University of California PLATELET FACTORS AND COGNITIVE IMPROVEMENT
US20230123357A1 (en) * 2020-03-04 2023-04-20 The Regents Of The University Of California Use of downstream factors in the klotho pathway to assess klotho activity
WO2024084400A2 (en) * 2022-10-17 2024-04-25 Bio Immunitas Ltd. Alpha 2 macroglobulin, soluble klotho and methods of use thereof
TW202434279A (zh) * 2022-10-28 2024-09-01 美商聯合生物技術公司 用於改善認知之方法
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
CN117797249A (zh) * 2023-11-14 2024-04-02 苏州祥沁医疗科技有限公司 基于mRNA的抗衰老抗老年痴呆预防及治疗疫苗
WO2025168038A1 (en) * 2024-02-07 2025-08-14 Kunming Institute Of Zoology, Chinese Academy Of Sciences Methods and compositions for ameliorating impairment of regenerative and cognitive function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452720A (en) 1980-06-04 1984-06-05 Teijin Limited Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5330900A (en) 1987-12-31 1994-07-19 Tropix, Inc. Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
WO1998029544A1 (en) 1996-12-26 1998-07-09 Kyowa Hakko Kogyo Co., Ltd. Novel peptide, novel dna, and novel antibody
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
ATE405286T1 (de) * 2001-03-23 2008-09-15 Chemo Sero Therapeut Res Inst Neue mittel zur linderung von motorischen störungen
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
US20040001859A1 (en) 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd klothoタンパク質および抗klothoタンパク質抗体ならびにそれらの用途
US20100330062A1 (en) 2007-05-08 2010-12-30 Koeffler H Phillip Klotho protein and related compounds for the treatment and diagnosis of cancer
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CN101711779B (zh) * 2008-10-08 2012-12-05 中南大学 垫状卷柏提取物在制备抗阿尔茨海默病药物中的用途
WO2011084452A1 (en) 2009-12-16 2011-07-14 Eli Lilly And Company Therapeutic uses of soluble alpha-klotho
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
JP2012184184A (ja) * 2011-03-04 2012-09-27 Nara Medical Univ 抗老化作用を有するヤドリギ抽出物
CN107810201A (zh) 2014-12-04 2018-03-16 诺华股份有限公司 使用klotho变体多肽的方法和组合物
AU2016215080B2 (en) 2015-02-06 2020-12-24 The Regents Of The University Of California Methods and compositions for improved cognition
EP3377091B1 (en) 2015-11-19 2023-09-20 Universitat Autònoma de Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments

Similar Documents

Publication Publication Date Title
JP2018509393A5 (https=)
Raghav et al. Nose-to-brain drug delivery: Challenges and progress towards brain targeting in the treatment of neurological disorders
US9757391B2 (en) Neuroactive steroids and their use to facilitate neuroprotection
JP2021518365A5 (https=)
JP2018520189A5 (https=)
EP3964203A1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
US9809823B2 (en) DNA aptamers for promoting remyelination
TW200918051A (en) Treatment of progressive neurodegenerative disease with ibudilast
EP4306167B1 (en) Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
US9486540B2 (en) Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
KR20090118078A (ko) 척수 손상 치료제
SG178942A1 (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
JP2018502872A5 (https=)
CN102387812A (zh) 神经损伤和神经退行性疾病后改善神经学预后的方法
WO2023063242A1 (ja) IFN-γへ選択的に結合するオリゴヌクレオチドを含有する自己免疫性疾患治療薬およびそのオリゴヌクレオチド
Buskila Drug therapy
WO2007139433A8 (en) Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application
US20220257582A1 (en) Treatment for synucleinopathies
EP2473174A2 (en) Ganglioside transmucosal formulations
Kshirsagar et al. Use of ketamine in refractory bronchospasm-a study of 20 cases
JP2013509422A5 (https=)
EP3697808B1 (en) Neuroprotective peptide
Jadeja et al. Comparative study of single dose pre-emptive pregabalin vs. Placebo for post-operative pain relief in middle ear surgery
JIANG et al. Research progress on the clinical application of esketamine
RU2013139704A (ru) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера